Instituto Rosenbusch S.A. (ROSE) - Total Assets
Based on the latest financial reports, Instituto Rosenbusch S.A. (ROSE) holds total assets worth AR$8.09 Billion ARS (≈ $5.85 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Instituto Rosenbusch S.A. net assets for net asset value and shareholders' equity analysis.
Instituto Rosenbusch S.A. - Total Assets Trend (2000–2024)
This chart illustrates how Instituto Rosenbusch S.A.'s total assets have evolved over time, based on quarterly financial data.
Instituto Rosenbusch S.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
Instituto Rosenbusch S.A.'s total assets of AR$8.09 Billion consist of 78.2% current assets and 21.8% non-current assets.
| Asset Category | Amount (ARS) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AR$0.00 | 11.6% |
| Accounts Receivable | AR$1.50 Billion | 19.9% |
| Inventory | AR$3.07 Billion | 40.7% |
| Property, Plant & Equipment | AR$0.00 | 0.0% |
| Intangible Assets | AR$0.00 | 0.0% |
| Goodwill | AR$0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how Instituto Rosenbusch S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Instituto Rosenbusch S.A. market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Instituto Rosenbusch S.A.'s current assets represent 78.2% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 11.6% of total assets in 2024, up from 1.4% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2000.
- Asset Diversification: The largest asset category is inventory at 40.7% of total assets.
Instituto Rosenbusch S.A. Competitors by Total Assets
Key competitors of Instituto Rosenbusch S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Instituto Rosenbusch S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.06 | 2.43 | 1.07 |
| Quick Ratio | 0.57 | 1.39 | 0.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AR$361.84 Million | AR$3.42 Billion | AR$30.53 Million |
Instituto Rosenbusch S.A. - Advanced Valuation Insights
This section examines the relationship between Instituto Rosenbusch S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 23.44 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -31.3% |
| Total Assets | AR$7.54 Billion |
| Market Capitalization | $5.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Instituto Rosenbusch S.A.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Instituto Rosenbusch S.A.'s assets decreased by 31.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Instituto Rosenbusch S.A. (2000–2024)
The table below shows the annual total assets of Instituto Rosenbusch S.A. from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | AR$7.54 Billion ≈ $5.46 Million |
-31.32% |
| 2023-12-31 | AR$10.98 Billion ≈ $7.95 Million |
+714.64% |
| 2022-12-31 | AR$1.35 Billion ≈ $975.41K |
+80.38% |
| 2021-12-31 | AR$747.29 Million ≈ $540.74K |
+10.60% |
| 2020-12-31 | AR$675.64 Million ≈ $488.90K |
+35.96% |
| 2019-12-31 | AR$496.94 Million ≈ $359.59K |
+35.50% |
| 2018-12-31 | AR$366.76 Million ≈ $265.39K |
+71.76% |
| 2017-12-31 | AR$213.52 Million ≈ $154.51K |
+7.92% |
| 2016-12-31 | AR$197.86 Million ≈ $143.17K |
+19.07% |
| 2015-12-31 | AR$166.17 Million ≈ $120.24K |
+18.06% |
| 2014-12-31 | AR$140.75 Million ≈ $101.85K |
+11.81% |
| 2013-12-31 | AR$125.89 Million ≈ $91.09K |
+9.57% |
| 2012-12-31 | AR$114.90 Million ≈ $83.14K |
+32.18% |
| 2011-12-31 | AR$86.92 Million ≈ $62.90K |
+18.38% |
| 2010-12-31 | AR$73.42 Million ≈ $53.13K |
+13.87% |
| 2009-12-31 | AR$64.48 Million ≈ $46.66K |
+12.26% |
| 2008-12-31 | AR$57.44 Million ≈ $41.56K |
+6.71% |
| 2007-12-31 | AR$53.83 Million ≈ $38.95K |
+10.94% |
| 2006-12-31 | AR$48.52 Million ≈ $35.11K |
+6.48% |
| 2005-12-31 | AR$45.57 Million ≈ $32.97K |
+16.50% |
| 2004-12-31 | AR$39.12 Million ≈ $28.30K |
+9.89% |
| 2003-12-31 | AR$35.60 Million ≈ $25.76K |
+20.45% |
| 2002-12-31 | AR$29.55 Million ≈ $21.38K |
+92.70% |
| 2001-12-31 | AR$15.34 Million ≈ $11.10K |
+4.25% |
| 2000-12-31 | AR$14.71 Million ≈ $10.64K |
-- |
About Instituto Rosenbusch S.A.
Instituto Rosenbusch S.A. manufactures and sells veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory complex, IBR, BVD, brucelosis, carbuncle, and other diseases; clostridial vaccines; vaccines for cattle, sheep, goats, horses, and dogs; and products for the prevention of pneumonia and calve diarrhea, and cattle infectious kera… Read more